Immunotherapy technology developer Actinium Pharmaceuticals has tapped radiopharmaceutical developer Zevacor Pharma as a manufacturing and supply partner for its upcoming radioimmunotherapy phase III trial.
Zevacor, formerly known as IBA Molecular North America, will provide the clinical production and supply of Iomab-B, a radioimmunotherapy agent intended for use in patients older than 55 prior to their receiving a bone marrow transplant for acute myeloid leukemia (AML).
Iomab-B has received an orphan drug designation from the U.S. Food and Drug Administration (FDA), and the pivotal phase III Study of Iomab-B in Elderly Relapsed/Refractory AML (SIERRA) is expected to enroll 150 patients, according to Actinium.
